Recombinant monoclonal antibody to CD2. Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.
Figure 1 Anti-Human CD2 Antibody (TAB-104) in ELISA
ELISA analysis of TAB-104 was performed by coating with Recombinant Human CD2 Protein (His Tag). Then blocked with BSA and incubated with Anti-Human CD2 Antibody (TAB-104). The HRP-conjugated goat anti-Human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 2 Anti-Human CD2 Antibody (TAB-104) in WB
Western blot analysis of TAB-104 was performed by loading Recombinant Human CD2 Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-104 and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Non-Reduced Antigen (1 μg)
Lane 2: Reduced Antigen (1 μg)
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-CD2 ADCC Recombinant Antibody (Siplizumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD2. Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B074(A) | Recombinant Anti-human CD2 Intrabody [(D-Arg)9] | PCA, WB, FuncS | scFv-(D-Arg)9 |
IAB-B074(G) | Recombinant Anti-human CD2 Intrabody [+36 GFP] | ELISA, IF, Neut, FuncS | scFv-(+36GFP) |
IAB-B074(T) | Recombinant Anti-human CD2 Intrabody [Tat] | ELISA, Neut, FuncS | scFv-Tat |
There are currently no Customer reviews or questions for TAB-104. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-104, RRID: AB_3111812)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.